Tc-99m sestamibi is one of the technetium radiopharmaceuticals.
- photon energy: 140 KeV
- physical half life: 6 hours
- normal distribution: thyroid, parathyroid, heart
- excretion: hepatobiliary
- target organ: colon, kidneys, bladder, gallbladder
Uses, doses and timings
- parathyroid scan
- adult dose: 20 mCi IV
- timing: early scan at 15 min; delayed scan at 2 hours
Tc99m-sestamibi is a radiopharmaceutical that is taken up by cells with a high concentration of mitochondria i.e. highly cellular/metabolically active tissues such as the heart but also abnormal tissues such as oxyphil cell parathyroid adenomas, myeloma and breast cancer (the basis of so-called scintimammography). This latter technique has a high specificity for cancer but uses significant radiation dose.
When the radiopharmaceutical is used for parathyroid imaging, immediate and delayed imaging of the neck and mediastinum is performed - parathyroid adenomas are best demonstrated on delayed imaging (1-2 hours).
- gallium agents
- iodine agents
- indium agents
- technetium agents
- thallium-201 chloride
- in vivo therapeutic agents